HOOKIPA shareholders approve doubling authorized shares to 200M and reverse split range

HOOKIPA Pharma Inc.

Authorized common shares increased from 100M to 200M via Certificate of Amendment.
Shareholders authorized reverse stock split in range of 1-for-2 to 1-for-10, if board elects.
Class III directors Julie O'Neill and Reinhard Kandera elected for three-year terms.
Stockholders ratified PwC Wirtschaftsprüfung GmbH as auditor for FY 2022.
2019 Stock Incentive Plan amended to increase authorized shares by 1M shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.